A phase I/II trial of high-dose methotrexate (HDMTX) followed by prophylactic glucarpidase in patients with impaired renal function and central nervous system lymphoma (CNSL).
Authors: Sven Liebig, Peggy Kießling, Sebastian Nagel, Susen Burock, Björn Chapuy, Kai Kappert, Ulrich Keller, Stefan Schwartz